| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
41 |
41 |
$0.00 |
| 85027 |
|
640 |
622 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
869 |
833 |
$0.00 |
| 3075F |
|
109 |
103 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,264 |
1,258 |
$0.00 |
| 99441 |
|
398 |
381 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
1,267 |
1,184 |
$0.00 |
| 86780 |
|
104 |
104 |
$0.00 |
| 87522 |
Neg quan hep c or qual rna |
127 |
126 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
2,415 |
2,194 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
223 |
218 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
515 |
489 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
402 |
401 |
$0.00 |
| 82607 |
|
16 |
16 |
$0.00 |
| 86592 |
|
14 |
14 |
$0.00 |
| 82043 |
|
91 |
88 |
$0.00 |
| 81001 |
|
31 |
29 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
325 |
316 |
$0.00 |
| 1111F |
|
131 |
115 |
$0.00 |
| 3074F |
|
447 |
418 |
$0.00 |
| 87340 |
|
69 |
69 |
$0.00 |
| 3079F |
|
145 |
142 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
12 |
12 |
$0.00 |
| 1220F |
|
86 |
85 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
19 |
19 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
137 |
134 |
$0.00 |
| 82728 |
|
18 |
18 |
$0.00 |
| 3080F |
|
17 |
15 |
$0.00 |
| 3044F |
|
259 |
256 |
$0.00 |
| 4450F |
|
40 |
39 |
$0.00 |
| 83550 |
|
19 |
19 |
$0.00 |
| 86706 |
|
13 |
13 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
16 |
15 |
$0.00 |
| 90656 |
|
29 |
29 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,015 |
808 |
$0.00 |
| 99442 |
|
355 |
332 |
$0.00 |
| 86703 |
|
314 |
313 |
$0.00 |
| 3078F |
|
450 |
416 |
$0.00 |
| 80061 |
Lipid panel |
1,147 |
1,146 |
$0.00 |
| 82540 |
|
91 |
88 |
$0.00 |
| 3077F |
|
55 |
49 |
$0.00 |
| 80074 |
|
12 |
12 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
183 |
179 |
$0.00 |
| 83540 |
|
19 |
19 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
26 |
26 |
$0.00 |
| 82274 |
|
31 |
31 |
$0.00 |
| 81003 |
|
14 |
14 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
19 |
19 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
41 |
41 |
$0.00 |
| 84439 |
|
14 |
14 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
23 |
13 |
$0.00 |